Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AstraZeneca PLC
Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.
The agency said its booster EUA decision was based on the immunogenicity studies that were submitted.
Moderna’s COVID-19 Vaccine Packaging Poses Booster Tracking, Safety Surveillance Challenges, Experts Say
Since company is using same vial and NDC code for primary series and booster dose, which is half the amount, immunization registries will not be able to capture how much Moderna vaccine an individual actually gets for their third dose.
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
- Other Names / Subsidiaries
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Cellective Therapeutics, Inc.
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma